I‑ON Digital Corp. Partners with Craft Capital to Strengthen Capital Strategy Ahead of 2026 Uplisting

IONI
November 24, 2025

I‑ON Digital Corp. announced a strategic engagement with Craft Capital Management, a capital‑markets advisory firm, to bolster its capital strategy and prepare for a potential uplisting to a national exchange in 2026.

The partnership will give I‑ON access to equity and debt financing, improve market visibility, and support upcoming financing initiatives. Craft Capital brings expertise in uplisting, structured capital formation, and institutional engagement, which will help I‑ON address liquidity challenges and scale its asset‑digitization business.

I‑ON, which trades on the OTCQB Venture Market, focuses on real‑world asset tokenization, converting in‑situ gold reserves into blockchain‑secured digital assets. Its flagship product, ION.au, is a gold‑backed digital asset that has attracted institutional interest. The RWA tokenization market is projected to expand significantly over the next decade, providing a tailwind for I‑ON’s growth.

CEO Carlos X. Montoya said the partnership will “assist us in preparing for increased institutional engagement, structured capital formation, and the requirements associated with a national exchange uplisting.” He added that the collaboration positions I‑ON for meaningful expansion in 2026 as the regulated RWA tokenization market accelerates.

Craft Capital is a full‑service broker‑dealer and investment bank with experience in NASDAQ and NYSE uplisting, and has limited underwriter capabilities. The engagement marks a key milestone in I‑ON’s strategy to transition from an OTC listing to a national exchange, aligning with its long‑term goal of becoming a leading infrastructure provider for regulated digital asset banking.

The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.